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With research and clinical advances over the past several decades, survival rates for 
childhood cancer have improved to greater than 80%. However, the path to survivorship 
poses a substantial burden to patients and families, with lengthy treatment courses 
requiring frequent hospital visits, and with late complications of treatment that can 
present years after therapy ends. This thesis explores each of these areas: one study 
investigating bone health and morbidity in leukemia and lymphoma survivors, and 
another study examining the cost burden to families of children during treatment for 
average-risk acute lymphoblastic leukemia (ALL). We aimed to determine the utility of 
surveillance, describe the burden to patients and families, and identify groups at highest 
risk who may benefit from intervention.  
 
We conducted a retrospective cross-sectional study of bone mineral density (BMD) 
surveillance in childhood cancer survivors attending survivorship clinics at Yale-New 
Haven Hospital and Seattle Children’s Hospital. This study found a substantial yield of 
survivors with BMD more than one standard deviation below norms, with higher yield of 
low lumbar spine BMD in survivors of white race, with low body mass index, or who 
were older at diagnosis, and higher yield of low total body BMD in survivors exposed to 
cranial radiation, with growth hormone deficiency after treatment, or with low body mass 
index. Survivors who had fractures post-therapy had a significantly lower BMD, but the 
	  
	  
absolute difference was not clinically meaningful. Our findings suggest that lumbar spine 
BMD surveillance has the greatest utility in survivors diagnosed at 10 years of age or 
older, and total body BMD surveillance may be best utilized in patients diagnosed at less 
than 10 years of age, as well as survivors exposed to cranial radiation or with growth 
hormone deficiency 
 
We conducted a prospective longitudinal study of financial toxicity in families of 
children undergoing treatment for average-risk ALL, which described a substantial 
educational, occupational, and financial cost burden that is highest early in treatment, but 
that persists until end of therapy. Occupational and opportunity costs are most 
noteworthy, with a sizable proportion of caregivers quitting or losing jobs, or not taking 
employment opportunities during their child’s ALL treatment.  
 
As the population of childhood cancer survivors continues to grow, it becomes 
increasingly important to understand the burden posed to survivors and families during 
and after therapy and identify groups at the greatest risk of higher costs and late 
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Chapter 1. Introduction 
 
Currently, approximately 80% of children diagnosed with cancer in childhood will 
become long-term survivors, as a result of improved treatments and novel therapies [1,2]. 
As of 2011 there were an estimated 388,000 childhood cancer survivors in the United 
States alone [3]. However, the path to cure requires intensive treatment with one or more 
modalities including chemotherapy, radiation therapy, surgery, or bone marrow 
transplant, and these therapies put survivors at risk for both short- and long-term 
complications that can affect all organ systems. The burden of these complications during 
and after an extensive treatment course on patients and families is considerable. This 
thesis seeks to describe two aspects of the burden of childhood cancer treatment, first by 
examining decreased bone mineral density as one potential late complication of 
treatment, and second by investigating financial toxicity to families during the prolonged 
treatment for acute lymphoblastic leukemia (ALL).  
 
The prevalence of late complications of treatment is sizable: about 73% of survivors will 
develop a chronic health condition within 30 years after diagnosis [4], and 20-50% of 
survivors will be affected specifically by an endocrine disturbance as a late complication 
of treatment [5]. Bone health is an area of particular interest, as many childhood cancer 
therapies are toxic to bone, but the long-term implications of reductions in bone mineral 
density (BMD) during childhood are unknown. Data is needed to understand the best 
ways to detect decreased BMD and to follow change in BMD over time in childhood 
cancer survivors. BMD is a well-established predictor of fracture risk in adults, and has 
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also been shown to be an indicator of fracture risk in children [6]. Evaluating fracture risk 
and outcomes in survivors is essential to understand the immediate and future morbidity 
it may cause for these patients.  
 
A significant aspect of the proposed study is our rigorous height correction of BMD 
standard deviation scores. In children, age, sex, height/bone size and pubertal maturation 
stage are major determinants of BMD development patterns [7]. BMD is measured using 
dual-energy x-ray absorptiometry (DXA) which calculates an areal measurement (g/cm2) 
that is adjusted for age, sex, and race based on normative data from the Bone Mineral 
Density in Childhood Study (BMDCS) to a standard deviation score (z-score). However, 
DXA is unable to measure bone depth, meaning that patients of short stature with smaller 
bones can appear to have a falsely low BMD. To address this concern, Zemel et al. used 
BMDCS and other normative data to create prediction equations that calculate height-
adjusted bone z-scores [8]. This method was shown to be least biased compared to other 
methods [7,8]. Our population of survivors has increased risk for short stature due to 
possible suboptimal nutrition during treatment, limited physical activity, and hormone 
disruption/delayed puberty. Because of this, we felt it was important to rigorously adjust 
DXA-calculated BMD for height for the most accurate analysis, using a method that, to 
our knowledge, has not been previously utilized in studies of BMD in childhood cancer 
survivors.  
 
Childhood cancer patients also face complications during treatment, which can impact 
not only their immediate health, but also all aspects of life outside the hospital. As 
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survival rates in pediatric cancer have improved, the scope of treatment goals has 
expanded to include reduced toxicity of therapies, improved patient quality of life during 
therapy, and lower risk of late complications of treatment [9.10]. Financial toxicity is one 
important measure of the burden families face during treatment. The term toxicity is used 
to describe the “side effect” of increased economic burden that is secondary to cancer 
treatment, and encompasses both increased out-of-pocket costs as well as opportunity 
costs. We assessed financial toxicity in families of children undergoing treatment for 
ALL, the most common pediatric cancer, affecting 3,100 newly-diagnosed children per 
year in the U.S. [11]. These patients were on a treatment protocol examining outcomes 
with reduced frequency of chemotherapy treatment, and potentially therefore reduced 
side effects and complications, during maintenance phase therapy as compared to the 
standard frequency of these chemotherapies. Understanding the financial toxicity to 
families and the patients at greater risk of high financial burden is essential, as financial 
toxicity has been shown to be related to risk of earlier relapse and overall survival in 
childhood ALL [12].   
 
In the following chapters, this thesis will investigate the burdens of childhood cancer 
therapy described above. By comprehensively evaluating the impact to families, we aim 
to identify patients at the highest risk of late complications or financial toxicity in order 
to guide future interventions.  
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Chapter 2. The burden of bone health decrements as a late effect of 
treatment: Bone Mineral Density surveillance and association with 
fracture in childhood leukemia and lymphoma survivors 
 
My role in this work: 
- Assembled multidisciplinary research team including pediatric oncologists and 
endocrinologists from Yale-New Haven Hospital and Seattle Children’s Hospital 
- Worked with Yale and Seattle IRB representatives to obtain IRB authorization 
agreement 
- Directed conference calls between faculty at both sites, setting agendas and 
moving project forward 
- Created database to compile data from over 1,000 patients 
- Designed statistical analysis plan, worked closely with biostatistician 
collaborator 
- Writing upcoming first-author manuscript 
 
Collaborators:	  Dr.	  Eric	  Chow,	  Pediatric	  Oncologist,	  Seattle	  Children’s	  Hospital	  
	   	   Dr.	  Kate	  Ness,	  Pediatric	  Endocrinologist,	  Seattle	  Children’s	  Hospital	  
	   	   Dr.	  Tom	  Carpenter,	  Pediatric	  Endocrinologist,	  Yale	  School	  of	  Medicine	  
	   	   Dr.	  Cemre	  Robinson,	  Pediatric	  Endocrinologist,	  Yale	  School	  of	  Medicine	  
	   	   Kyaw	  Sint,	  Biostatistics	  Ph.D.	  Candidate,	  Yale	  University	  
	  
	  
Status	  of	  this	  work:	  This	  work	  was	  selected	  for	  oral	  presentation	  at	  the	  2017	  
International	  Conference	  on	  Long-­‐Term	  Complications	  of	  Treatment	  of	  Children	  and	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Adolescents	  for	  Cancer.	  	  A	  manuscript	  is	  in	  preparation	  for	  submission	  to	  the	  Journal	  of	  
Clinical	  Oncology.	  	  
Bloomhardt HM, Sint K, Rotatori J, Chow E, Kadan-Lottick NS. Bone mineral density 
surveillance in survivors of childhood leukemia and lymphoma. Oral Presentation: 15th 
International Conference on Long-Term Complications of Treatment of Children and 
Adolescents for Cancer; 2017 June 15; Atlanta, GA. Also presented as a poster at the 
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Background 
 
Childhood leukemia and lymphoma survivors in particular are at risk of developing low 
bone mineral density (BMD) because bone metabolism can be impacted by cancer 
therapies often used in these diseases, reduced weight-bearing activity, nutritional 
deficiencies, and endocrinopathies secondary to treatment. Furthermore, childhood is a 
critical period for bone mass acquisition, with at least 90% of peak bone mass, a major 
determinant of osteoporosis lifetime risk, acquired by age 18 [6,13]. A bone mineral 
content deficit of one standard deviation below norms has been associated with an 89% 
increased risk of fracture in healthy children [14]. It has been previously estimated that 
up to 45% of childhood cancer survivors under 18 years old have BMD more than one 
standard deviation below norms, though estimates have varied widely [15,16]. A study in 
ALL survivors indicated a 6-fold greater incidence of fractures compared to healthy 
controls (0.12 and 0.02 per person per year, respectively) [23], while a study of long-term 
childhood cancer survivors found that 35% of survivors had at least one fracture in their 
lifetime, which was a significantly lower prevalence compared to a sibling cohort group 
(39%) [24]. What is not known is the optimal BMD surveillance strategy for survivors, 
and the association of low BMD with fractures in this group.  
 
Much of what is known about bone mineral density in childhood cancer survivors is from 
small cohort studies, did not adjust BMD for height, and/or did not explore association 
with fracture. These studies have been helpful to elucidate risk factors for reduced BMD 
in survivors. The leukemic process itself can cause defective bone mineralization [17]. 
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Treatment exposure risk factors include glucocorticoids [18], methotrexate [19], and 
cranial radiation [20]. Late complications of treatment that put survivors at risk include 
hypogonadism [21] and growth hormone deficiency [22]. The clinically meaningful 
outcome of abnormal BMD in survivors is risk of fractures. There have been inconsistent 
findings regarding fracture risk, with a large multisite mixed childhood cancer diagnosis 
cohort showing a lower risk of fracture in survivors compared to siblings, but a study of 
61 Acute Lymphoblastic Leukemia (ALL) survivors showing a six times greater fracture 
risk compared to healthy controls [23,24]. Further studies are needed with larger cohorts 
and height-adjusted BMD to further elucidate risk factors in survivors and clarify the 
association of low BMD with fracture.  
 
The Children’s Oncology Group consensus guidelines recommend that every survivor 
with high-risk exposures for low BMD be evaluated with a dual-energy x-ray 
absorptiometry (DXA) scan or quantitative CT when beginning follow-up care at a 
survivorship clinic, with repeated evaluation as clinically indicated [25]. A recent study 
determined the yield of baseline bone density surveillance for low BMD (defined as 2 
standard deviations below the mean in patients less than 20 years old and 1 standard 
deviation below the mean in patients greater than 20 years old) to be 23.2% among a 
population of 370 childhood cancer survivors of mixed diagnoses attending a 
survivorship clinic, with significantly higher yield in male and nonobese survivors [26]. 
Our current study will extend these interesting data with a larger sample restricted to 
leukemia and lymphoma survivors, a subgroup at particular risk because of multiple 
therapies toxic to bone. Our study will also rigorously correct BMD measurements for 
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height in pediatric patients, as described by the Bone Mineral Density in Childhood 
Study, for greatest accuracy of standard deviation score.  
 
Childhood is a critical period for determinants of future bone health, and may also be a 
critical time for intervention to prevent future bone-related morbidity. We hope to better 
understand the utility of baseline DXA screening in childhood cancer survivors, to 
identify which patients are at greatest risk for low BMD, to determine which bone sites 





Aim 1: To examine the distribution of BMD deficits in childhood cancer survivors with 
varied treatment durations, exposures, and late complications.  
We hypothesize that BMD deficits will be more prevalent and at a higher severity in the 
lumbar spine and femoral neck as trabecular bone, which is more metabolically active, is 
present in these locations.  
 
Aim 2: To further evaluate the yield of recommended BMD surveillance among 
childhood leukemia and lymphoma survivors attending survivorship clinics in New 
Haven, Connecticut and Seattle, Washington. 
We hypothesize that BMD surveillance will identify a substantial yield of patients with 
BMD in the "low” range (greater than 1 standard deviation below norms), but a lower 
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yield of patients with a BMD in the “very low” range (greater than 2 standard deviations 
below norms).  
 
Aim 3: To identify patient and treatment characteristics that may confer increased risk of 
low BMD. 
We predict that survivors	  exposed	  to	  dexamethasone,	  high-­‐dose	  methotrexate,	  higher	  
doses	  of	  alkylating	  agents,	  craniospinal	  radiation,	  and/or	  total	  body	  irradiation	  will	  
have	  a	  higher	  surveillance	  yield	  due	  to	  their	  direct	  effects	  on	  bone	  or	  effects	  on	  the	  
hormonal	  axis.	  We	  also	  predict	  that	  survivors	  experiencing	  growth	  hormone	  deficiency	  
or	  hypogonadism	  secondary	  to	  treatment	  will	  have	  a	  higher	  surveillance	  yield. When 
examining survivors of ALL, we predict that boys will have a higher surveillance yield 
due to the longer treatment course and greater treatment exposures compared to girls.  
 
Aim 4: To create predictive models in adjusted analyses for patients with abnormal DXA 
results. 
We hypothesize that radiation exposures and endocrinopathies that are a late 
complication of treatment will remain significant in adjusted analyses as they may have 
more significant effects on hormone axes and bone mineralization than other treatment 
exposures.  
 
Aim 5: To determine the relationship between BMD and fractures post-therapy in 
survivors. 
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We predict that survivors with a post-therapy fracture will have significantly lower BMD 
than survivors without a fracture history.   
 
Aim 6: To examine change in BMD over time in survivors with repeat DXA scan 
surveillance. 
We hypothesize that survivors found to have low bone mineral density on a baseline DXA 
screen will have increased bone mineral density on a repeated DXA scan due to 
behavioral changes such as increased weight-bearing activity and/or calcium and 





My role in this work is described at the beginning of this chapter. I received assistance 
with a minimal amount of data entry, and with statistical software coding. I completed all 
other procedures myself with the support of Dr. Kadan-Lottick.  
 
Study Design and Eligibility 
Our cross-sectional study consisted of all survivors of childhood leukemia and lymphoma 
who attended survivorship clinics at Yale-New Haven Hospital or Seattle Children’s 
Hospital who met the following criteria: diagnosed with leukemia or lymphoma at age 
<20 years, completed DXA scan at ≥2 years after end of therapy, no pre-existing 
conditions affecting BMD. All participants received surveillance for decreased BMD and 
other late complications per Children’s Oncology Group consensus guidelines, which 
recommend survivors with glucocorticoid, methotrexate, or cranial radiation treatment 
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exposure receive a baseline DXA scan upon entry into survivorship care (≥2 years after 
end of therapy), with repeated evaluation as clinically indicated.  
 
The Yale University Human Investigations Committee approved this study. The Seattle 
Children’s Hospital Human Investigations Committee established an IRB Authorization 
Agreement with the Yale University Human Investigations Committee for inclusion of 
attendees of Seattle Children’s Hospital Cancer Survivor Program.  
 
Patient & Treatment Characteristics 
Demographics, treatment history, and medical outcomes were abstracted from medical 
records and survivorship clinic databases. Treatment exposures abstracted included: high-
dose methotrexate (defined as cumulative dose ≥5000 mg/m2), cyclophosphamide 
equivalent dose (method described by Green et al. [27]), at least some dexamethasone 
exposure as compared to prednisone only or no glucocorticoid treatment (glucocorticoid 
doses were not available), cranial radiation (includes total body irradiation), total body 
irradiation (yes/no). Medical outcomes evaluated were body mass index (BMI) (kg/m2), 
and growth hormone deficiency, hypogonadism, and hypothyroidism as documented by 
clinician. Fractures post-therapy were patient-reported at survivorship clinic visits. Digit 
fractures were excluded. Long bone fractures were defined as patient-reported leg, arm, 
ankle, or wrist fractures.  
 
Bone Mineral Density Evaluation 
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Bone mineral density was evaluated with a dual-energy x-ray absorptiometry (DXA) 
scan. Both centers used the Hologic Discovery A densitometer, with pediatric edge 
detection software version 12.3-13.3. DXA scans completed on Hologic densitometers 
and using the same software can be compared in analyses due to measurement reliability. 
Lumbar spine was the primary BMD measurement region chosen due to availability of 
data from both clinical centers, its accuracy and reproducibility in pediatric patients 
[7,28], and as a measure of primarily trabecular bone which is more metabolically active 
[29], and has been shown to be more susceptible to bone mineralization impacts 
secondary to ALL therapies than cortical bone [30]. Total body BMD was available for 
96% of patients evaluated at Seattle Children’s Hospital, but only 20% of patients 
evaluated at Yale-New Haven Hospital because of hospital practices. Total body BMD 
was analyzed for patients of Seattle Children’s Hospital only, to provide a measure of 
both trabecular and cortical bone. Other sites measured included total body less head 
BMD (excludes cranial bones, which are less affected by metabolic and environmental 
factors), total hip BMD, and femoral neck BMD, which are reported for surveillance 
yield and fracture association analyses only but not evaluated in further analyses. BMD 
values were compared to normative data reference values [31] to calculate age- and sex- 
matched standard deviation score, or z-score. As DXA calculates areal BMD rather than 
volumetric BMD, it is known that patients of short stature may have falsely low BMD on 
DXA [32]. Therefore, we adjusted BMD z-score for height in patients aged 4-20 at the 
time of evaluation using the method described by Zemel et al. [8] performed by the Bone 
Mineral Density in Childhood Study calculator (https://bmdcs.nichd.nih.gov/zscore.htm). 
If a survivor had multiple DXA scans, the first scan more than 2 years after end of 
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therapy was defined as the baseline scan, and the next consecutive scan was defined as 
the follow-up scan.   
 
Low BMD was defined as at least one standard deviation below age- and sex-matched 
norms, in order to capture a range of BMD deficits in survivors. Very Low BMD was 
defined as at least two standard deviations below age- and sex-matched norms, 
comparable to current International Society for Clinical Densitometry definitions. Yield 
of screening for the purposes of this analysis was defined as the proportion of patients 
with Low BMD out of those screened.  
 
Data Analysis 
Analyses were done with SAS version 9.4. Descriptive statistics were used to examine 
patient characteristics of the cohort. Chi squared test of independence and Fisher’s exact 
test were used to compare yield by patient characteristic and treatment exposure 
subgroups. Univariate logistic regression was used to evaluate unadjusted predictors of 
low BMD. Separate multiple logistic regression models adjusting for all factors 
simultaneously were used to explore adjusted predictors of low BMD, one model 
including treatment factors and another including late complication factors to avoid 
collinearity. Independent samples T-tests were used to compare mean BMD z-score 









In total, 934 survivors were diagnosed with leukemia or lymphoma from 1975-2013 at 
age <20 years. Excluded were 11 patients due to pre-existing conditions affecting BMD, 
i.e. trisomy 21 or congenital endocrinopathies, and 142 patients for having a DXA scan 
<2 years after the end of therapy, which did not meet COG Long-Term Follow-Up 
guidelines. 542 survivors were eligible for our study (Figure 1). Survivors were 
diagnosed at a mean age of 7.42 years (SD 5.2), with a representation of young children, 
pre-pubertal, and adolescent aged patients. Survivors were evaluated at a median age of 
15.1 years, which was a median 4.1 years after end of therapy. The cohort is 51.5% 
female, predominantly patients of white race (82.8%) though 15% were Hispanic, and a 
majority were Acute Lymphoblastic Leukemia (ALL) survivors (65.1%). Almost all 
survivors (95%) were treated with glucocorticoids, so we examined any dexamethasone 
exposure, a more potent steroid (59.6%), as compared to no dexamethasone exposure 
(40.4%). Other treatment exposures included 85.1% of patients treated with at least some 
alkylating agent, 25.8% treated with high-dose methotrexate, 20.7% treated with cranial 
radiation, and 8.1% treated with total body irradiation (Table 1).  When comparing 
demographics by survivorship clinic, we noted that patients attending Seattle Children’s 
Hospital survivorship clinic were significantly younger at evaluation (mean 14.1 years vs. 
19.2 years, p<0.0001) and were evaluated at significantly fewer years after end of therapy 
(mean 4.7 years vs. 9.2 years, p<0.0001). The Yale cohort contained more male patients 
(60% vs. 47%, p=0.01). Significantly more Yale patients were treated with prednisone 
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only or no steroids (56% vs. 34%, p<0.0001), and more with high-dose methotrexate 
(43% vs. 20%, p<0.0001). There were no other significant differences in the cohort by 
survivorship clinic, and survivors from Yale and Seattle were analyzed as one group in 
further analyses.  
 































N=934 Diagnosed with leukemia or 
lymphoma <20 years old   
N=695 DXA scan completed   
N=684 No known pre-disposing 
conditions   
N=542 Eligible patients   
N=239 No DXA scan   
N=11 Prior condition 
affecting BMD 
(e.g. trisomy 21)  
N=142 DXA scan <2 
years after end of 
therapy  
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Table 1. Patient characteristics at baseline DXA scan N (%) 








  66 (12.2%) 
120 (22.1%) 






















  23   (4.3%) 
  30   (5.6%) 





  83 (15.5%) 
453 (84.5%) 
Diagnosis  
Acute Lymphoblastic Leukemia 





  35   (6.5%) 
  79 (14.6%) 


















  81 (14.9%) 
409 (75.5%) 
  52 (9.6%) 
















  44   (8.1%) 
497 (91.9%) 
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Frequency of bone health decrements  
Table 2 shows the number of patients out of 542 total survivors found to have BMD 
within 1 standard deviation below norms (normal BMD), those greater than 1 standard 
deviation below norms (Low BMD), and the subset of those who had BMD greater than 2 
standard deviations below norms (Very Low BMD), for each body site measured. Nearly 
all patients had available lumbar spine and total hip BMD measurements (>99%). Only 
75% of the cohort had total body BMD measurements: 96% of patients at Seattle 
Children’s Hospital and 20% of patients at Yale-New Haven Hospital. Further analyses 
examine total body BMD for Seattle Children’s Hospital patients only. The femoral neck 
BMD, which is a specific segment of total hip, was missing for 56.5% of our cohort. 
Total body less head BMD was only available for 101 survivors in our cohort, but was 
examined as a measure that eliminates variability of cranial BMD. Overall, the 
prevalence of Low BMD in our cohort was substantial, but when examining the group as 
a whole, the mean BMD z-score at all measurement sites was within one standard 
deviation below norms, or in normal range. Table 2 displays the mean BMD z-score at 
each measurement site, with total body less head having the lowest mean BMD z-score at 
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Table 2. BMD deficits by body site measured  
 
 Total Body Total Body  
Less Head 
Lumbar Spine Total Hip Femoral neck 
       N         N          N N N 
Normal BMD  
(<1 SD below norms) 
275   65 448 455 224 
Low BMD  
(> 1 SD below norms) 
132   36   93   83   63 
Very Low BMD  
(> 2 SD below norms) 
  39   14   19   14   12 
Total N 407 101 541 538 236 
% missing 25.0% 81.4% 0.2% 0.07% 56.5% 
      
Mean (SD) -0.58 (1.1) -0.64 (1.2) 0.057 (1.1) 0.17 (1.1) -0.19 (1.3) 
 
Yield of BMD Surveillance 
Overall Sample: In this cohort, Low BMD was identified in 37.6% of survivors and Very 
Low BMD in 11.3% of the survivors in at least one of the five measurement sites, using 
COG consensus guidelines for BMD surveillance (Figure 2). We focused on lumbar 
spine as a reliable and reproducible measurement site in children that was available for 
99% of our cohort. The yield of lumbar spine BMD surveillance was 17.2% Low BMD 
and 3.5% Very Low BMD. We conducted a sub-analysis of total body BMD in patients 
of Seattle Children’s Hospital survivorship clinic and found a yield of 32.4% Low BMD 
and 9.6% Very Low BMD. Other sites measured included total body less head, which 
had the highest yield of Low BMD of any individual site at 35.6% and 13.4% 
respectively. Total hip measurement had a yield of 15.4% Low BMD and 2.6% Very 
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Patient factors/treatment exposures – Lumbar Spine BMD: We examined lumbar spine 
BMD by patient and treatment exposure subgroups to identify survivors who may have a 
greater utility of surveillance (Table 3A). Patients who were older at diagnosis had a 
significantly higher yield of lumbar spine BMD surveillance, increasing with age to 
29.2% of those diagnosed at age 15-19 years found to have Low BMD. Patients of white 
race (vs. non-white race) and with lower BMI also had a higher yield of lumbar spine 
Low BMD surveillance, consistent with known risk factors for low BMD. There was no 
difference in yield of lumbar spine Low BMD surveillance for treatment factors including 
dexamethasone exposure, alkylating agent exposure (quantified as cyclophosphamide 
equivalent dose), high-dose methotrexate exposure, cranial radiation, and total body 
irradiation, and no difference in yield for late complications of treatment including 
growth hormone deficiency, thyroid hormone deficiency, and hypogonadism. There was 
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also no difference in yield for survivors taking calcium and/or vitamin D 
supplementation.  
 
We also examined yield of lumbar spine Very Low BMD surveillance by patient and 
treatment groups. This analysis was limited by low patient numbers, but found that again 
older ages at diagnosis had a higher yield of surveillance, with 7.6% of survivors 
diagnosed at age 10-14 and 10.8% of those diagnosed at age 15-19 having lumbar spine 
Very Low BMD. Survivors who were older at evaluation also had a significantly higher 
yield of surveillance, with 7.6% of survivors evaluated at 20 years or older found to have 
lumbar spine Very Low BMD. Survivors not exposed to high-dose methotrexate had 
significantly higher yield of lumbar spine Very Low BMD (4.6%) compared to those 
exposed (0.7%), though this analysis was done with very small sample sizes (n<9). There 
was also a higher yield of lumbar spine Very Low BMD in underweight (1.8%) and 
normal weight (6.0%) BMI as compared to overweight or obese BMI (0%) Other 
treatment exposures and late complications of treatment did not have a difference in yield 
of lumbar spine Very Low BMD.  
 
Overall, the only patient factors that demonstrated higher yield of lumbar spine Low or 
Very Low BMD, a measure of primarily trabecular bone, were older age at diagnosis and 
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Table 3A. Proportion of patients with lumbar spine Low BMD and Very Low BMD by 
patient and treatment characteristics 
 % Low 
BMD 
(N=93) 














 0.002  
  1.6 
  0.0 
  7.6 
10.8 
<0.0001 








   0.06  
  1.7 
  2.9 
  7.6 
   0.04 








   0.3    
  5.4 
  1.0 
  2.2 







   0.1  
  3.2 
  3.8 






  9.5 
   0.03  
  3.6 
  3.2 
   0.8 
Diagnosis 
Acute Lymphoblastic Leukemia 








   0.1    
  3.4 
  0.0 
  7.7 
  1.3 
   0.1 






   0.7  
  0.7 
  4.6 
   0.03 






   0.2  
  2.8 
  3.6 







   0.3  
  5.1 
  3.4 
   0.6 








  8.7 
  9.1 
   0.01  
  1.8 
  6.0 
  0.0 
  0.0 
   0.01 
*Also examined but not significantly different yields were: duration of therapy, dexamethasone 
exposure, cyclophosphamide equivalent dose, cranial radiation, total body irradiation, thyroid 
hormone deficiency, calcium supplementation, vitamin D supplementation 
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Patient factors/treatment exposures – Total Body BMD: We conducted a sub-analysis of 
total body BMD, and found that survivors with cranial radiation exposure, growth 
hormone deficiency, and lower BMI had a significantly higher yield of total body BMD 
surveillance (Table 3B), with 45.0% of survivors with cranial radiation exposure, 54.6% 
of survivors with growth hormone deficiency, and 44.9% of survivors with underweight 
BMI found to have total body Low BMD (as compared to survivors with no cranial 
radiation exposure, no growth hormone deficiency, and other BMI categories, 
respectively). There was no difference in yield of total body BMD surveillance for other 
treatment factors and late complications of treatment examined, as well as again no 
difference in yield in survivors taking calcium and/or vitamin D supplementation. 
Notably, 50.0% of survivors with hypogonadism diagnosed after treatment were found to 
have total body Low BMD, but this yield of surveillance was not significantly higher 
than that of survivors without hypogonadism (31.6%).  
 
For total body Very Low BMD, survivors treated with cranial radiation had a 
significantly higher yield of surveillance at 16.3%, compared to 8.0% in those not treated 
with cranial radiation, and white survivors had a higher yield of surveillance (11.0%) 
compared to non-white survivors (3.8%). Other treatment factors and late complications 
of treatment did not have a significant difference in yield of total body Very Low BMD.  
 
Overall, the notable patient and treatment factors that demonstrated higher yield of total 
body Low or Very Low BMD, a measure of both cortical and trabecular bone, were 
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Table 3B. Proportion of patients with total body Low BMD and Very Low BMD by 
patient and treatment characteristics 
 % Low 
BMD 
(N=132) 














   0.3  
  7.7 
  8.5 
16.9 
15.2 
   0.1 








   0.1  
  6.9 
12.4 
  6.7 
   0.3 








   0.2  
13.3 
  7.6 
  5.5 







   0.1  
  8.2 
12.5 







   0.1  
11.9 
  4.1 
   0.05 
Diagnosis 
Acute Lymphoblastic Leukemia 








   0.9  
10.7 
  9.5 
10.3 
  9.6 







   0.007  
16.9 
  8.7 
   0.04 






   0.01  
15.0 
10.1 







   0.1  
16.7 
10.1 
   0.4 










   0.01  
14.1 
10.2 
  6.4 
  8.1 
   0.6 
*Also examined but not significantly different yields were: duration of therapy, dexamethasone 
exposure, cyclophosphamide equivalent dose, high-dose methotrexate exposure, total body 
irradiation, thyroid hormone deficiency, calcium supplementation, vitamin D supplementation 
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Yield in ALL patients by sex: We also conducted a sub-analysis of BMD surveillance 
yield for survivors of ALL by sex, as the treatment course is substantially longer for boys 
than girls (3 vs. 2 years). Table 4 shows that the yield of Low BMD surveillance at any 
site is significantly higher for boys, 15.2%, compared to girls, 7.5%, who are survivors of 
childhood ALL. However, there is no significant difference by sex when looking at Low 
BMD of the total body (boys 37.4% compared to girls 26.6%) or lumbar spine (boys 
18.8% compared to girls 12.2%) alone.  
 




Female ALL survivors 
% Low BMD 
Male ALL survivors 
% Low BMD 
 
p-value 
Total Body 26.6 37.4 0.06 
Lumbar Spine 12.2 18.8 0.09 
Total Hip 15.6 15.2 0.9 
Any Site 7.45 15.2 0.02 
 
 
Predictors of Low BMD 
We next examined the association of patient and treatment variables with lumbar spine 
and total body BMD in univariate and multivariate analyses to determine the probability 
of Low BMD in patient and treatment subgroups, and identified several factors associated 
with greater odds of Low BMD (Tables 5, 6A, and 6B).  
 
Lumbar Spine Low BMD probabilities – univariate analysis: Older age at diagnosis was 
associated with greater odds of lumbar spine Low BMD, with 2.35 greater odds at 10-14 
years (95% CI 1.3-4.3) and 3.15 greater odds at 15-19 years (95% CI 1.7-6.1) as 
compared to 0-4 years at diagnosis. Patients of non-white race had 0.45 lower odds (CI 
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0.2-0.9) of lumbar spine Low BMD as compared to white patients. Patients with 
underweight and normal BMI had 2.36 (CI 1.0-5.6) and 2.85 (CI 1.3-6.2) respectively 
greater odds of lumbar spine Low BMD as compared to overweight patients. Other 
patient, treatment, and late complication factors were not associated with lumbar spine 
low BMD in univariate analysis.  
 
Lumbar Spine Low BMD probabilities – multivariate analysis: In one model looking at 
treatment exposures and adjusting for sex, race, and age at diagnosis, none of the 
treatment exposures examined (dexamethasone exposure, cyclophosphamide equivalent 
dose, high-dose methotrexate exposure, and cranial radiation exposure) were associated 
with greater odds of lumbar spine Low BMD. Race was a significant factor in the model, 
with survivors of non-white race having 0.40 lower odds of having lumbar spine Low 
BMD (95% CI 0.2-0.9). Older age at diagnosis was also significant, with survivors 
diagnosed at 15 years old or older at 3.78 greater odds (95% CI 1.7-8.2) of having lumbar 
spine Low BMD at surveillance. In a separate model examining late complications of 
treatment and adjusting for sex, race, and age at diagnosis, only age at diagnosis and BMI 
were significantly associated with lumbar spine Low BMD. Survivors diagnosed at 15 
years or older had 5.93 greater odds (95% CI 2.7-13.2) as compared to those diagnosed at 
age 0-4 years. Survivors with underweight BMI had 4.68 times greater odds (95% CI 1.8-
12.4) and survivors with normal BMI had 3.35 times greater odds (95% CI 1.5-7.6) as 
compared to survivors with overweight BMI. Growth hormone deficiency, thyroid 
hormone deficiency, and hypogonadism were not significant factors in this model (Table 
6A).  
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Total Body Low BMD probabilities – univariate analysis: Survivors with cranial 
radiation exposure had 2.0 greater odds of total body Low BMD (95% CI 1.2-3.3) and 
those with growth hormone deficiency had 3.13 greater odds of total body Low BMD 
(95% CI 1.2-7.9) than survivors without these exposures or late effects of therapy. 
Patients with underweight BMI had 2.61 (1.3-5.4) greater odds of total Low BMD as 
compared to patients of other BMI categories. Other patient, treatment, and late 
complication factors were not associated with total body low BMD in univariate analysis 
(Table 5).  
 
Total Body Low BMD probabilities – multivariate analysis: As with lumbar spine Low 
BMD, a multiple regression model adjusting for sex, race, and age at diagnosis showed 
that none of the treatment exposures examined, including cranial radiation exposure, 
which was significant in univariate analysis, were associated with greater odds of total 
body Low BMD. Race, sex, and age at diagnosis were also not significant in the adjusted 
model. In a separate model examining late complications of treatment and adjusting for 
sex, race, and age at diagnosis, age at diagnosis was a significant factor, but no subgroup 
alone was significant. BMI was also significantly associated with total Low BMD, with 
survivors with underweight BMI at 4.62 times greater odds (95% CI 2.1-10.5) as 
compared to patients of overweight BMI. Growth hormone deficiency was marginally 
significant in the model, with 2.92 greater odds (95% CI 1.0-8.6, p=0.052) in survivors 
with this late complication of treatment. Thyroid hormone deficiency and hypogonadism 
were not significant factors in this model (Table 6B).  
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Overall, in adjusted analyses, older age at diagnosis and white race were associated with 
greater odds of lumbar spine Low BMD. Lower BMI was also highly associated with 
greater odds of Low BMD in models for both measurement sites. However, no treatment 
exposures or late complications of treatment were predictive of Low BMD in these 
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Table 5. Predictors of lumbar spine and total body Low BMD in univariate analysis 
 
 Lumbar Spine Low BMD Total Body Low BMD 
(*=reference) OR (95% CI) p-value OR (95% CI) p-value 



























































Acute Lymphoblastic Leukemia (*) 






















































*Also examined but not significant were: duration of therapy, ethnicity, dexamethasone exposure, 
cyclophosphamide equivalent dose, high-dose methotrexate exposure, total body irradiation, 
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Table 6A. Predictors of lumbar spine Low BMD in multivariate analysis 
  
Model 1: Treatment exposures odds ratio plot 
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Model 2: Late complications of treatment odds ratio plot 
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  0.01 
 
  0.06 
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Table 6B. Predictors of total body Low BMD in multivariate analysis 
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  0.08 
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  0.0001 
  0.3 
 
  0.03 
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Association of BMD with fracture outcomes 
As a measure of the clinical implications of low BMD, we examined fracture outcomes in 
our cohort. One hundred and thirty-six of 542 survivors reported a fracture post-therapy, 
or 25% of our cohort. Table 7 shows the distribution of fractures reported in our cohort, 
with 59 in the upper extremity long bones, 28 in the lower extremity long bones, and 23 
in other sites (including jaw, sternum, rib, clavicle, and spine). Table 8 shows the 
relationship between height-adjusted BMD z-score and at least one fracture in any site 
(excluding digits). Survivors who had a fracture post-therapy had significantly lower z-
scores measured for total body, lumbar spine, and total hip than those without a fracture. 
The mean z-score for survivors with a fracture was -0.86 for total body (compared to -
0.59 for survivors without a fracture), -0.26 for lumbar spine (compared to 0.14 for 
survivors without a fracture), and -0.03 for the total hip measurement (compared to 0.23 
for survivors without a fracture). Of note, the mean z-score for all sites in patients who 
experienced a fracture after therapy ended was higher than our classification of Low 
BMD (z-score<-1.0).  
 




















59 28 15 23 
Proportion of all 
fractures in cohort 
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 Mean z-score (SD) Mean z-score (SD) p-value 
Total Body -0.86 (1.1) -0.59 (1.1)   0.04 
Total Body Less Head 




 0.14 (1.1) 
  0.7 
<0.001 
Femoral Neck  -0.30 (1.0) -0.17 (1.3)   0.6 
Total Hip -0.03 (1.1)  0.23 (1.1)   0.03 
 
 
Fracture mechanism: We also categorized fractures into known pathologic, known 
traumatic, and unknown mechanism. When comparing known pathologic fractures to 
known traumatic or unknown mechanism fractures (Table 9), we found no statistically 
significant difference in mean z-score between patients with and without known 
pathologic fractures post-therapy. However, there were only 6 known pathologic 
fractures in the cohort, which limited our analysis.    
 
 













 Mean z-score (SD) Mean z-score (SD) p-value 
Total Body 
Total Body Less Head 
-1.56 (1.2) 
     N/A 
-0.83 (1.1) 
-0.89 (1.6) 
  0.1 
  N/A 
Lumbar Spine  -0.74 (0.7) -0.24 (1.1)   0.3 
Femoral neck  -1.04 (N/A) -0.23 (1.2)   0.5 




	   36	  
Long bone fractures: Table 10 shows the odds of Low BMD in patients with fractures. 
Survivors with any fracture (excluding digits) had 2.27 greater odds of lumbar spine Low 
BMD (95% CI 1.4-3.7), but not significantly increased odds of total body Low BMD. 
Survivors with a long bone fracture had greater odds of Low BMD, 2.74 greater odds of 
lumbar spine Low BMD (95% CI 1.6-4.7) and 1.82 greater odds of total body Low BMD 
(95% CI 1.1-3.1).  
 
Table 10. Fracture as a predictor of Low BMD 
(*=reference) Lumbar spine Low BMD Total Body Low BMD 
 OR (95% CI) p-value OR (95% CI) p-value 



















Change in BMD over time 
We looked at change in BMD over time for the subset of patients who had follow-up 
DXA scans aiming to better understand the utility of continued BMD surveillance and 
monitoring. Table 11 shows the mean change in z-score in the 67 patients who had a 
repeat DXA scan for follow-up BMD surveillance. In the total body less head, femoral 
neck, and total hip z-score measurements, there was mean interval improvement in z-
score. However, the magnitude of improvement was minimal: in total body less head, 
mean improvement was 0.15 (SD 0.5), in femoral neck mean improvement was 0.12 (SD 
0.7), and in total hip mean improvement was 0.003 (SD 0.6). However, in the total body 
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and lumbar spine z-score measurements, the mean change from baseline DXA to follow-
up DXA was a decrease of -0.01 in the total body measurement (SD 0.7) and -0.13 in the 
lumbar spine measurement (SD 0.8). Notably, there was not a significant difference in the 
mean change in z-score for different durations of time since the prior DXA scan, with the 




Table 11. BMD change over time 
 












Measurement site Mean change 
in z-score (SD) 
 




Total Body Less Head 
 -0.01   (0.7) 
  0.15   (0.5) 
 0.01   (0.4) 
 0.16   (0.7) 
  0.14 (0.6) 
  0.13 (2.8) 
 -2.06 (N/A) 
N/A 
   0.001 
   0.9 
Lumbar Spine  -0.13   (0.8)  0.008 (0.7)  -0.16 (0.7) -0.24 (1.2)    0.6 
Femoral neck   0.12   (0.7) -0.03   (0.5)   0.11 (0.7)   0.23 (0.8)    0.6 
Total Hip   0.003 (0.6)  0.05   (0.6)   0.03 (0.6) -0.09 (0.8)    0.8 
 
*N for each group is for overall sample, N may be less for individual measurement site 
 
Overall, a substantial proportion of survivors in our cohort had fractures after the end of 
their cancer treatment, and those with fractures had significantly lower BMD on average 
and also had greater odds of BMD in the Low category. We did not observe a significant 
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Discussion 
 
This cross-sectional analysis of BMD surveillance according to COG consensus 
guidelines in survivors of leukemia and lymphoma demonstrated a substantial proportion 
of survivors having decrements in bone health. Of our survivorship cohort, 37.6% had 
Low BMD in at least one measurement site, but only 11.3% had Very Low BMD in at 
least one measurement site, consistent with previous studies [26,33,34]. Even fewer 
survivors, 3.5%, were found to have Very Low BMD at the lumbar spine, a reliable 
measurement site in children. These findings suggest that though BMD greater than one 
standard deviation below the mean is uncovered in many leukemia and lymphoma 
survivors, it is reassuring that few of these patients have BMD that is greater than two 
standard deviations below the mean, a measure that would be of greater concern. 
Importantly, we examined fracture outcomes in our cohort to evaluate if this cause of 
morbidity is related to decreased BMD. Survivors with a history of fracture post-therapy 
had significantly lower height-adjusted BMD z-score in the total body, lumbar spine, and 
total hip measurements, and had more than two times greater odds of lumbar spine Low 
BMD. However, the average BMD z-score in survivors with a history of fracture was 
within 1 standard deviation below the mean in all sites measured, and would not meet our 
Low BMD criteria, suggesting that BMD surveillance according to these standards would 
not identify all patients at higher risk of fracture.  
 
The current study also aimed to identify patient and treatment groups with a higher yield 
of BMD surveillance to determine which survivors may most benefit from DXA 
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evaluation. There was a significantly higher yield of lumbar spine BMD surveillance at 
the lumbar spine in patients who were older at diagnosis, of white race, and with 
underweight or normal BMI at DXA evaluation. Total body BMD surveillance had a 
higher yield in survivors treated with cranial radiation, with growth hormone deficiency 
as a late complication of treatment, of white race, and with lower BMI. Surveillance yield 
was much higher overall for total body BMD measurements than lumbar spine 
measurements, ranging from 25-60% yield for total body Low BMD versus 8-29% yield 
for lumbar spine Low BMD depending on subgroup. Notably, treatment exposures 
previously shown to increase risk for BMD did not have significantly higher yield of 
lumbar spine or total body Low BMD in our cohort, including high-dose methotrexate, 
higher doses of alkylating agents, and total body irradiation. Including dexamethasone, a 
more potent steroid, in the glucocorticoid regimen was also not associated with a higher 
frequency of Low BMD. Additionally, survivors with growth hormone deficiency or 
hypogonadism identified as a late complication of treatment of did not have a 
significantly higher yield of lumbar spine Low BMD in our cohort. Altogether, these 
findings suggest that lumbar spine BMD surveillance has the greatest utility in survivors 
diagnosed at 10 years of age or older, and total body BMD surveillance may identify a 
greater proportion of survivors with bone health decrements, and could be best utilized in 
patients diagnosed at less than 10 years of age, as well as survivors exposed to cranial 
radiation or with growth hormone deficiency.  
 
We were able to conduct a sub-analysis of BMD surveillance yield in over 350 ALL 
survivors, who comprised the majority of our cohort. This growing group is important to 
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consider, as improved therapies and supportive care have made cure rates for average-
risk ALL greater than 90% [11] but with substantial treatment exposures and a 2-3 year 
treatment duration that pose potential risk for decreased BMD. We found that more than 
twice as many male survivors of ALL were found to have Low BMD in at least one 
measurement site compared to female survivors of ALL. Though there was no significant 
difference in the more reliable lumbar spine measurement, it is important to recognize 
that males treated for ALL may be at greater risk for decreased BMD with a 3-year 
treatment course and thereby prolonged exposure to glucocorticoids and methotrexate, 
and may also have a higher yield of surveillance requiring interpretation and further 
evaluation by clinicians. 
 
To our knowledge, this is the largest study to date examining BMD surveillance in 
leukemia and lymphoma survivors that rigorously corrects BMD for height, using a 
method described by Zemel et al. [8] that was shown to be least biased compared to other 
methods [7,8], with the main limitation being that it does not factor in pubertal 
maturation. Another strength of our study is thorough documentation of fracture history 
per patient report, for over 500 survivors. The incidence of fractures in children is 
substantial, with estimates ranging from 1.3-3.6% of healthy children per year [35,36] 
resulting in 5-26 activity-restricted days, a significant burden in children. In healthy 
children, a prospective cohort study of over 6000 children showed a 1.12 greater odds of 
fracture per standard deviation decrease in BMD at 9.9 years of age, and 8.9% of children 
having a fracture over the 2-year study period [14]. Childhood cancer survivors are 
suspected to be at greater risk of fractures due to treatment exposures and the effects on 
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bone development during childhood, and 25% of our cohort of survivors followed for a 
median of 4 years after end of therapy reported fractures. Though we have no comparison 
group for our retrospective cohort, the finding of positive fracture history in one-quarter 
of our sample is noteworthy. However, it is remarkable that previous large studies in 
childhood cancer survivors have found no difference in fracture rate between survivors 
and siblings at a mean 22.7 years after end of therapy [16], and no association between 
DXA- or quantitative CT- measured BMD and fracture history [37]. Our findings expand 
on these studies, with a cohort that includes a sizeable number of patients who were 
adolescent and post-pubertal at DXA evaluation, and patients who ranged from 2 to 35 
years after the end of therapy. The long-term risk of fracture in childhood cancer 
survivors remains an important area of investigation. 
 
The findings of our study should be interpreted in the context of several limitations. 
Findings in survivors attending survivorship clinic may not be generalizable to all 
leukemia and lymphoma survivors. Our cohort had an under-representation of patients of 
Black race as compared to the demographics of each city: our New Haven cohort had 6% 
Black patients, while 2016 surveys found 33% Black individuals [70]. Our Seattle cohort 
had 3% Black and 6% Asian patients, while 2010 census data found 8% Black and 14% 
Asian individuals [71]. We did not have detailed information on health behaviors in our 
cohort, including tobacco use, diet, and exercise. Our data on fracture outcomes was 
based on patient report, and less symptomatic pathologic fractures may have been missed. 
Lastly, while the length of follow-up in our cohort was up to 35 years after the end of 
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therapy, the median follow-up was 4 years, and a longer follow-up time may be necessary 
to determine the full extent of BMD deficits in survivors.  
 
Another important consideration is the implications for survivors and their providers 
when decreased BMD is identified. The COG long-term follow-up guidelines 
recommend that survivors at risk of or found to have decreased BMD conduct regular 
weight-bearing activity and have adequate vitamin D and calcium intake via diet or 
supplementation [25]. Prior studies have shown lower BMD in survivors not taking 
vitamin D or calcium supplementation [38,39] while our study found no difference in 
yield of low BMD surveillance in survivors taking vitamin D or calcium supplements. 
Notably, a recent meta-analysis of studies including over 50,000 participants in 
randomized clinical trials found no significant difference in hip fracture risk in adults 
taking calcium or vitamin D supplements [40] though some studies of calcium and 
vitamin D supplementation in children with prolonged glucocorticoid exposure as 
treatment of juvenile rheumatoid arthritis or idiopathic juvenile osteoporosis have shown 
improvement in BMD decrements and decreased fracture rate [41,42]. Studies of this 
kind in long-term childhood cancer survivors would be beneficial to guide providers in 
establishing interventions for survivors found to have decreased BMD. 
 
In conclusion, the yield of BMD surveillance according to current COG consensus 
guidelines is substantial, but it is reassuring that few survivors have BMD that would be 
considered low for age by International Clinical Society on Densitometry definitions. 
Survivors who are older at diagnosis, who are treated with cranial radiation, or have 
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growth hormone deficiency post-therapy may be at greater risk for decreased BMD and 
have a greater utility of surveillance. Our data suggests that survivors treated with high-
dose methotrexate or stem cell transplant, currently recommended in the COG Long-
Term Follow-Up guidelines to receive BMD surveillance, do not have a higher yield of 
surveillance than survivors without these treatment exposures and surveillance may have 
lesser utility in these groups than expected. We observed an association between Low 
BMD and fractures after childhood cancer treatment ends. Further research is necessary 
to clarify the use of BMD surveillance as an indicator of fracture risk, one aspect of the 
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Chapter 3. The financial toxicity burden of pediatric cancer therapy: 
non-medical costs to patients and families during Acute Lymphoblastic 
Leukemia treatment 
 
My role in this work: 
- Conducted literature review 
- Compiled survey data from Children’s Oncology Group sites to create a database 
for over 600 patients 
- Worked with health economist collaborator to design cost burden models 
- Conducted preliminary statistical analyses, ongoing work designing statistical 
analysis plan for Children’s Oncology Group analyses  
 
Collaborators:	  Dr.	  Amy	  Davidoff,	  health	  economist,	  Yale	  School	  of	  Public	  Health	  
	  
Status	  of	  this	  work:	  This	  project	  is	  ongoing	  as	  Children’s	  Oncology	  Group	  data	  analysis	  
must	  be	  done	  by	  a	  group	  biostatistician	  which	  requires	  waiting	  in	  an	  analysis	  queue.	  
Planned	  and	  ongoing	  work	  includes:	  	  
- Awaiting report of therapeutic study outcomes to determine if visit frequency is 
associated with financial toxicity 
- Merging cost burden data with Pediatric Health Information System data in 
collaboration with Dr. Richard Aplenc, Children’s Hospital of Philadelphia   
- Writing first-author manuscript 
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Background 
 
There are approximately 3,100 children diagnosed with Acute Lymphoblastic Leukemia 
(ALL) in the United States each year, accounting for almost one-third of new pediatric 
cancers [11]. As therapies and supportive care have improved, cure rates for children with 
newly-diagnosed average-risk acute lymphoblastic leukemia (AR-ALL) currently exceed 
90% [43]. However, the 2-3 year duration of therapy includes frequent clinic visits, 
unexpected hospitalizations, and other treatment-related complications, posing a 
significant burden to families. Families of children with cancer may experience lost 
income or productivity and increased out-of-pocket expenses associated with being a 
caregiver to the child [44]. Almost a quarter of U.S. families with a child undergoing 
cancer treatment reported a “great deal” of financial hardship as a result of their child’s 
illness [45]. This economic hardship caused great additional emotional stress for more 
than 90% of Australian families affected [46], and is therefore an important issue to 
address. In recent years, this economic ‘side effect’ of pediatric cancer treatment has been 
given a name: financial toxicity. Most previous studies of the financial toxicity of 
pediatric cancer have focused on cost-effectiveness of treatment [47-49], had small 
sample sizes, and were conducted outside the U.S. [44,50]. Less is known about the 
financial toxicity to families of children on U.S. treatment protocols, and about the costs 
throughout therapy. 
 
A major nonmedical cost to families with a child undergoing cancer treatment is loss of 
parental wages. Though this is difficult to measure directly, one study estimated this cost 
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as almost $5,000 per year in 1985 [51]. At 6 months after diagnosis, 25% of families had 
lost more than 40% of annual household income due to treatment-related work 
disruptions. The burden of lost wages was greater on low-income families, who lost a 
significantly greater proportion of annual income than higher income families [52]. 
Parents of a child undergoing treatment for ALL are at a significantly increased risk of 
loss of employment, and 51% of parents declined occupational opportunities due to their 
child’s diagnosis [53]. Other studies have shown that 56-84% of U.S. families with a 
child undergoing cancer treatment experienced some work disruption [45,52], and one-
third of caregivers reported quitting or changing jobs as a result of their child’s illness 
[54]. Families in which a caregiver had quit or changed jobs reported 13.9 points higher 
financial burden than families without employment disruptions [55], indicating that this is 
a substantial component of the financial toxicity to families with a child undergoing 
cancer treatment. Another major component of financial toxicity is out-of-pocket costs 
such as food, travel, or childcare. These can be the most burdensome costs on a family 
because they must be paid immediately, and are rarely reimbursed, in contrast to medical 
bills [56]. Previous retrospective studies have found that treatment-related family-borne 
costs are at least one-third of the average family’s after-tax income in Canadian families 
[47], and 38% of the gross annual family income in U.S. families [51]. Non-medical costs 
have been shown in one group of child and adolescent cancer patients to be 92% of a 
family’s financial burden [57], and therefore are an essential area of investigation. 
 
Another aspect of the burden of ALL treatment on families is the educational and family 
functioning “cost”. Children undergoing treatment for ALL miss significantly more 
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school than the general school aged population [58]; one study found that patients missed 
between 58 and 90 days of school on average during the first six months of treatment, 
depending on distance from their treatment center [54]. Teachers of Italian children 
previously treated for leukemia saw difficulties in attendance, concentration, and low 
energy in these students [59]. Rates of absenteeism and educational cost to children 
receiving modern treatment for B-ALL specifically have not been previously reported. 
Families also experience a high incidence of major life changes in the first year of ALL 
treatment, including home relocation, divorce/separation, and changes to family planning 
[53]. These changes, as well as changes to school and work attendance, may affect family 
functioning. Unhealthy family functioning in families of children with standard-risk acute 
lymphoblastic leukemia was found to be predictive of anxiety and depression in these 
children [60], but an association with nonmedical costs of care has not been previously 
studied.   
 
This prospective, longitudinal, multi-site study aims to comprehensively quantify the 
financial toxicity of average risk B-ALL treatment sustained by children and families 
throughout treatment. Patients were recruited from those enrolled on Children’s 
Oncology Group (COG) AALL0932 AR-ALL trial at sites across the U.S., and surveyed 
at time points ranging from 2 months after diagnosis to the end of therapy on various 
measures of nonmedical costs. This is a very large, geographically diverse pediatric 
oncology patient cohort with extensive temporal cost information relative to previous 
studies. We sought to identify predictors of higher nonmedical costs related to patient 
demographics and treatment schedule. ALL is the most common pediatric cancer, and it 
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is important to prospectively measure the financial toxicity to families facing a 
particularly long treatment course, and to identify at-risk families or treatment timepoints 




Aim 1: To quantify the severity of nonmedical cost burden of care of children with 
average risk B-ALL enrolled in COG AALL0932 with respect to missed days of 
school/daycare/work patients and their parents and out-of-pocket spending.  
We hypothesize that there will be a substantial nonmedical cost of care to families with a 
child being treated for average risk B-ALL, particularly in missed days of work and 
opportunity cost to parents.  
 
Aim 2: To identify predictors of higher cost burden in families of children with average 
risk B-ALL in order to assess targets for future interventions.   
We predict that higher nonmedical costs will be associated with male sex, lower 
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Methods 
 
My role in this project is described at the beginning of the chapter. This ancillary study 
was already designed and undergoing data collection at the time I joined the team. The 
database creation and below analyses are my own work.  
 
Study design and eligibility 
This prospective longitudinal cohort study was an ancillary study integrated within the 
frontline average risk B-ALL groupwise phase III therapeutic protocol within the 
Children’s Oncology Group, which has treatment arms comparing two methotrexate 
doses and reduced frequency of chemotherapy pulses during maintenance phase therapy 
versus standard frequency.  Eligibility criteria for our ancillary study include: enrollment 
on the average risk B-ALL post-induction treatment phase arm of this study, at least one 
parent with speaking and written knowledge of English, patient 4 years of age or older at 
the time of study consent, and no history of pre-leukemia diagnosis of a 
neurodevelopmental disorder.  
 
The Yale University Human Investigations Committee, as well as the Human 
Investigations Committee at all participating Children’s Oncology Group sites, approved 
this study.  
 
Procedures 
Data was collected by paper surveys at scheduled time points during therapy. There were 
scheduled time points for collection of data based on the standardized treatment protocol, 
which includes an induction, consolidation, and maintenance phase, lasting a total of 2 
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years in girls and 3 years in boys due to their poorer prognosis [19]. The survey time 
points are displayed in table 1. They include: end of consolidation therapy (~2 months 
after diagnosis), day 29 of maintenance cycle 1 (~8 months after diagnosis), day 29 of 
maintenance cycle 4 (~17 months after diagnosis), day 29 of maintenance cycle 7 for 
boys/off-therapy for girls (~25 months after diagnosis), and off-therapy for boys (~37 
months after diagnosis). There are 4 time points evaluated for girls and 5 time points 
evaluated for boys.   
 
Table 1. Survey timepoints during average-risk ALL therapy 
 
(T=timepoint) Time since diagnosis Phase of therapy 
T1   ~2 months End of consolidation phase 
T2   ~8 months Day 29 of maintenance cycle 1 
T3 ~17 months Day 29 of maintenance cycle 4 
T4 ~25 months Day 29 of maintenance cycle 7 – BOYS 
Off therapy – GIRLS 
T5 ~37 months Off therapy – BOYS  
 
Surveys 
The primary survey used in this study was entitled the “Family Life with Leukemia” 
Survey. It is a 17 question survey created for the purposes of this study that obtains 
caretaker-reported data on changes in a child’s school services or attendance, changes in 
responding caretaker and spouse’s (if applicable) employment status and missed days of 
work, and estimated out-of-pocket costs over the past 4 weeks. It also asks a free text 
question: “please share other ways your family life has changed since your child’s 
diagnosis of leukemia for the better or for the worse.” This survey was completed at all 
time points.  
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Parents also completed a demographic questionnaire at the first time point, which was a 5 
question survey asking questions about family structure, parental education, and family 
income. Other surveys completed at all time points not utilized in the current analysis 
included a pediatric quality of life survey, a family assessment device, and a child 
vulnerability scale.   
 
Data Analysis 
The below analyses are preliminary only, and finalized analyses will be conducted 
by Children’s Oncology Group statisticians as is required by the group. Analyses 
were done with IBM SPSS Statistics for Macintosh, Version 22.0. Descriptive statistics 
were used to characterize the nonmedical costs of care to families of children with 
average risk B-ALL. Independent samples T-tests and ANOVA were used to compare 
frequency of nonmedical costs by patient and family characteristics. With the assistance 
of Dr. Amy Davidoff, a health economist at the Yale School of Public Health, we are 
conducting ongoing analyses to create models utilizing generalized estimating equations 
to incorporate time-varying clinical, family, and system factors and to evaluate the 
association between events that occur at one time point and effects on other time points. 







	   52	  





































*Based on Andersen Healthcare Utilization Model	   	  
 
Individual	  Characteristics:	  
• Predisposing	  	  
	   -­‐	  demographic	  factors	  (age,	  sex,	  race)	  
-­‐	  social	  factors	  (low	  SES)	  
-­‐	  beliefs	  
• Need	  
-­‐	  perceived	  (child	  vulnerability)	  





-­‐	  usual	  source	  of	  care	  
	  
Disease	  Characteristics:	  
• Side	  effects	  (Grade	  3+	  toxicity,	  allergic	  
reaction)	  
• Relapse/change	  in	  risk	  evaluation	  
(would	  go	  off	  study)	  
• Study	  delay	  (low	  counts)	  
• More	  complex	  treatment	  course	  (study	  
arm	  randomization)	  
Family	  Characteristics:	  
• Resources	  	  
-­‐ Employment	  (and	  changes)	  
-­‐ Health	  insurance	  
-­‐ Income	  
-­‐ Opportunities	  (employment)	  
• Organization	  
-­‐ number	  of	  parents/caregivers	  
-­‐ geography	  	  
Utilization	  
• Missed	  days	  (school/work)	  
• Out-­‐of-­‐pocket	  costs	  
• Job	  security	  (lost	  hours,	  job)	  
Quality	  of	  Life	  
• Patient	  quality	  of	  life	  
• Family	  functioning	  	  
• Family	  life	  events	  
OUTCOMES	  
	  




In total, 594 children with average-risk ALL were enrolled between August 2010 and 
April 2013, with an 81% participation rate (table 2). Slightly fewer than half were female 
(46.6%). Participants were diagnosed at a mean age of 6.0 years (SD 1.6), with about half 
of patients being school-aged at diagnosis. The majority of our cohort was of non-
Hispanic White race (69.5%), but also included 15.7% Hispanic patients and 4.2% non-
Hispanic Black patients. A range of socioeconomic status was represented in the cohort, 
with 43.2% of families having an annual household income less than $50,000 and 17.2% 
of families over $100,000. A large portion of the cohort, 43.9%, had household sizes of 5 
people or more. The majority of caregivers (80.2%) were married or living as married. 
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Table 2. Patient and treatment characteristics for children treated for average-risk ALL 
 
Characteristic    N (%) 
Sex 
     Male 




Age at diagnosis in years, mean (SD)  6.0 (1.6) 











     White, non-Hispanic 
     Black, non-Hispanic 
     Hispanic/Latino 
     Other or unknown 
 
413 (69.5) 
  25   (4.2) 
  93 (15.7) 
  63 (10.6) 
Annual household income 
     <$50,000 
   $50,000-999,999 




  83 (17.2) 
Household size 
     ≤4 people 




Marital status of caregivers 
     Not married 





     Less than college 
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Financial toxicity during ALL Therapy 
Financial toxicity was assessed with several complementary measures. At 2 months post-
ALL diagnosis (timepoint 1), the burden to families was particularly high: 68.1% of 
children required new or additional school accommodations, 25.6% of children had 
missed more than 21 days of school in the past 4 weeks, 16% of surveyed parents had 
quit their job, 33.9% of caregivers and 19.2% of partners had reduced their work hours, 
and 16.8% of caregivers and 15.4% of partners missed more than 10 days of work in the 
past 4 weeks. Financial toxicity to the pediatric patient, to families, and in terms of out-
of-pocket costs are examined below.  
 
Cost burden to pediatric patient: Table 3A displays the frequency of surveyed education 
burden to children treated for average-risk ALL. The highest number of missed school 
days was at timepoint 1, with more than half of patients enrolled in school missing more 
than 21 days of school over the past month, and 64% of patients enrolled in school 
missing more than 10 school days. At timepoints 2-5, only 7-10% of patients enrolled in 
school missed more than 10 days of school over the past month. The proportion of 
patients requiring new or additional school or special education services declined after 
timepoint 2, but remained high at the end of therapy, with about half of patients needing 
school accomodations and about 20% of patients needing special education services at 
timepoint 4 and 5 (end of therapy for girls and boys, respectively). At the end of therapy 
timepoint, more than 80% of patients enrolled in school missed at least some school over 
the past month.  
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Table 3A. Frequency of educational burden to children during average-risk ALL 
treatment 
 
Education Burden T1 T2 T3 T4 T5 



















  77 (50.7) 









































  17   (4.4) 
  36   (9.2) 
  23   (5.9) 
  19   (4.9) 





  34 (10.8) 
138 (43.8) 
  22   (7.0) 
    7   (2.2) 
    3   (1.0) 




  33   (9.9) 
152 (45.8) 
  42 (12.7) 
  14   (4.2) 
    3   (0.9) 
    6   (1.8) 
  55 (16.6) 
 
 
  19 (12.0) 
  83 (52.5) 
  12   (7.6) 
    5   (3.2) 
    3   (1.9) 
    4   (2.5) 
  32 (20.3) 
 
 
  23 (17.7) 
  68 (52.3) 
  14 (10.8) 
    2   (1.5) 
    2   (1.5) 
    4   (3.1) 
  17 (13.1) 
 
Cost burden to caregivers: In terms of the occupational burden to families during ALL 
therapy, the proportion of primary caregivers who reported voluntarily quitting a job 
since their child’s diagnosis peaked at timepoint 3 (~8 months after diagnosis), at 21.5%. 
The highest proportion of caregivers and partners reducing work hours occurred at 
timepoint 1, at one third, and declined over therapy, with a slight increase in caregivers 
reducing hours at timepoint 5. The proportion of caregivers and partners reporting losing 
a job since their child’s diagnosis increased over therapy and peaked at timepoint 5, with 
9.2% of surveyed caregivers and 8.7% of partners. A substantial proportion of caregivers 
and partners also did not start a new job (up to 14.2% of caregivers and 6.7% of partners) 
or accept a job opportunity (up to 5.3% of caregivers and 3.8% of partners). The number 
of work days missed by caregivers and partners was highest at timepoint one, with 31.0% 
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of caregivers and 64.3% of partners missing at least some work in the past 4 weeks. The 
proportion of caregivers and partners missing work days declined over therapy, with 38-
40% of caregivers and 33-36% of partners missing at least some work at the end of 
therapy time points.  
 
Cost burden to families: In terms of family events, 9.9% of primary caregivers reported 
separating or divorcing their partner since their child’s diagnosis at the end of therapy 
timepoint. The data displayed in table 3 indicates the absolute proportion of families 
experiencing each burden, but does not show how many families experienced more than 
one of these occupational or family events. However, it is notable that at each time point, 
37.2-50.0% of responding caregivers reported experiencing none of the listed events 
(voluntarily quit job, reduced work hours, lost job/laid off, did not start a job but wanted 
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Table 3B. Frequency of occupational and relationship burden to primary caregiver of 
child being treated for average-risk ALL   
 
Occupational Burden T1 T2 T3 T4 T5 
(T=timepoint) N (% respondents) 
Since child’s diagnosis: 
Quit job 
Reduced hours 
Lost job/laid off 
Did not start a job but wanted to 
Did not accept a job opportunity 
Separated/divorced partner 
None of the above 
 
  78 (16.0) 
166 (33.9) 
  10   2.0) 
  46   (9.4) 
    8   (1.6) 
    2   (0.4) 
202 (41.3) 
 
  56 (17.3) 
  91 (28.2) 
  23   (7.1) 
  46 (14.2) 
  12   (3.7) 
  17   (5.3) 
120 (37.2) 
 
  67 (21.5) 
  66 (21.2) 
  19   (6.1) 
  42 (13.5) 
    8   (2.6) 
  19   (6.1) 
135 (43.3) 
 
  19 (11.9) 
  35 (21.9) 
  11   (6.9) 
  22 (13.8) 
    5   (3.1) 
    7   (4.4) 
  80 (50.0) 
 
  17 (13.0) 
  33 (25.2) 
  12   (9.2) 
  17 (13.0) 
    7   (5.3) 
  13   (9.9) 
  61 (46.6) 








Not working for compensation 
 
 
  75 (12.5) 
  55   (9.2) 
  30   (5.0) 
  20   (3.3) 
  12   (2.0) 




  97 (31.1) 
106 (80.3) 
    5   (1.6) 
    2   (0.6) 
    4   (1.3) 
    5   (1.6) 
  93 (29.8) 
 
 
  86 (29.2) 
107 (36.3) 
    8   (2.7) 
    3   (1.0) 
    3   (1.0) 
    1   (0.3) 
  87 (29.5) 
 
 
  51 (34.0) 
  55 (36.7) 
    2   (1.3) 
    0   (0.0) 
    2   (1.3) 
    2   (1.3) 
  38 (25.3) 
 
 
  53 (41.4) 
  39 (30.5) 
    7   (5.5) 
    2   (1.6) 
    0   (0.0) 
    1   (0.8) 
  26 (20.3) 
 
Table 3C. Frequency of occupational and relationship burden to non-surveyed caregiver 
of child being treated for average-risk ALL  
 
Occupational Burden T1 T2 T3 T4 T5 
(T=timepoint) N (% respondents) 
Since child’s diagnosis: 
Quit job 
Reduced hours 
Lost job/laid off 
 Did not start a job but wanted to 
 Did not accept a job opportunity 
None of the above 
 
    6   (1.2) 
  94  (19.2) 
  16   (3.3) 
  12   (2.5) 
    9   (1.8) 
276 (56.4) 
 
  14   (5.1) 
  42 (15.3) 
  18   (6.6) 
    7   (2.6) 
    3   (1.1) 
192 (70.1) 
 
  13   (5.0) 
  37 (14.1) 
  16   (6.1) 
  13   (5.0) 
    6   (2.3) 
181 (69.1) 
 
    9   (6.5) 
  12   (8.6) 
    9   (6.5) 
    4   (2.9) 
    5   (3.6) 
  99 (71.2) 
 
    2   (1.9) 
    9   (8.7) 
    9   (8.7) 
    7   (6.7) 
    4   (3.8) 
  74 (71.2) 








Not working for compensation 
 
 
  75 (23.5) 
110 (34.5) 
  46 (14.4) 
  15   (4.7) 
    8   (2.5) 
  26   (8.2) 




  91 (32.3) 
    8   (2.8) 
    2   (0.7) 
    3   (1.1) 
  13   (4.6) 




  76 (28.9) 
    5   (1.9) 
    0   (0.0) 
    0   (0.0) 
    3   (1.1) 
  24   (9.1) 
 
 
  76 (55.1) 
  45 (32.6) 
    1   (0.7) 
    3   (2.2) 
    1   (0.7) 
    0   (0.0) 
  12   (8.7) 
 
 
  63 (61.2) 
  28 (27.2) 
    4   (3.9) 
    0   (0.0) 
    0   (0.0) 
    2   (1.9) 
    6   (5.8) 
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Out-of-pocket financial burden: Average out-of-pocket financial burden was categorized 
by type of expense, including childcare, transportation, housing, medical, and total cost 
(table 4). Medical out-of-pocket costs were the highest, particularly at timepoint 1, with 
an average $929 cost (SD $6282) over the past 4 weeks. Average transportation and food 
costs were also high, $177 and $165 over the past 4 weeks, respectively. The mean total 
financial burden to families at timepoint 1 was $1,381 (SD $6413), but ranged as high as 
$101,500. Mean costs in all types of expenses significantly decreased over each timepoint 
(all p<0.02), with the exception of housing, which increased at timepoint 5 and was not 
significantly different across timepoints.  
 
Table 4. Monetary cost burden estimates across treatment 
 
 T1 T2 T3 T4 T5 p-value  
Expense 







 Mean (SD)  
Childcare     $61.56 
(250) 






  $16.46 
(66) 
0.02 
Transportation   $176.51 
(286) 






  $54.82 
(94) 
>0.001 
Food   $165.17 
(468) 






  $46.28 
(78) 
>0.001 








  $62.24 
(249) 
0.2 
Medical out of 
pocket 
























  $0 -          
  $7350.00 
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Predictors of higher cost burden during ALL therapy 
As the highest proportion of families with educational, occupational, and financial burden 
was observed at timepoint 1, we examined patient characteristics that may predict higher 
cost burden at this timepoint, about 2 months after diagnosis. Table 5 shows the mean 
missed days of school and work by patient characteristics at timepoint 1. There was no 
significant difference in mean missed days of school or work by sex, age at diagnosis, or 
race, with the exception of non-Hispanic Black patients having significantly fewer missed 
days of work by the spouse of the surveyed parent as compared to patients of other races. 
There was no significant difference in missed days of school or work depending on 
annual household income, though there was a trend for more missed days of school and 
more missed days of work by the spouse of the surveyed parent in households with lower 
annual incomes. There was no significant difference in missed days of school or work by 
household size, marital status of the caregivers, or by maternal education.  
 
Table 6 presents the mean out-of-pocket financial burden at timepoint 1 by patient 
characteristics. There was no significant difference in out-of-pocket costs by sex or age at 
diagnosis. There was a significantly higher financial burden in non-Hispanic black 
patients (mean $5,295, SD $21,275) as compared to patients of other races (p=0.03). 
There was no significant difference in mean out-of-pocket costs depending on annual 
household income, household size or marital status of caregivers. Families with mothers 
who had attended at least some college had significantly higher financial burden (mean 
$1,825, SD $7852) compared to families with mothers who had not attended college.  
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Table 5. Comparison of missed days of school and work by patient characteristics at 




















Overall 15.3   (9.3)    9.7   (9.8)  5.9 (7.1)  
Sex 
     Male 
     Female 
 
15.5   (8.9) 
15.1   (9.8) 
0.7  
   9.5   (9.7) 












16.0   (9.3) 
16.1   (9.3) 
14.2   (9.1) 
0.7  
  8.0   (9.1) 
  9.7   (9.9) 
10.3 (10.3) 








     White, non-Hispanic 
     Black, non-Hispanic 
     Hispanic/Latino 
     Other or unknown 
 
15.0   (9.4) 
17.6 (11.0) 
15.5   (9.2) 
16.1   (9.3) 
0.9  
  9.5   (9.5) 
11.6 (12.1) 








Annual household income 
     <$50,000 
   $50,000-999,999 






  9.3   (9.9) 
10.5   (9.9) 







     ≤4 people 





10.1   (9.8) 





Marital status of caregivers 
     Not married 
     Married or living together 












     Less than college 
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Table 6. Monetary cost burden estimates by patient characteristics at timepoint 1 (~2 
months after diagnosis) 
 




Overall $1381 (6413)  
Sex 
     Male 
     Female 
 
$1016 (2077) 
  $993 (1698) 
0.9 






  $964 (2496) 
$2594 (12685) 




     White, non-Hispanic 
     Black, non-Hispanic 
     Hispanic/Latino 




  $733 (2697) 
$1048 (1356) 
0.03 
Annual household income 
     <$50,000 
   $50,000-999,999 







     ≤4 people 
     >4 people 
 
$1783 (8581) 
  $931 (2124) 
0.2 
Marital status of caregivers 
     Not married 






     Less than college 
     At least some college 
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Discussion 
 
This prospective, longitudinal analysis of financial toxicity to families during average-
risk ALL therapy demonstrated a substantial burden, particularly in terms of patient 
schooling, parent/spouse employment and opportunity cost, and out-of-pocket costs. Cost 
burden was highest early in therapy and generally declined across timepoints. However, 
the proportion of patients affected at the end of therapy timepoint remained sizeable, with 
more than 80% of patients missing at least some school, 33-40% of parents and spouses 
missing at least some work, and monthly out-of-pocket costs greater than $350. There 
were no patient characteristics that predicted higher cost burden in our cohort, with the 
exception of increased missed days of work by the partner of the surveyed caregiver and 
increased total out-of-pocket costs in patients of non-Hispanic Black race. Interestingly, 
there was no difference in missed school days by age at diagnosis, suggesting that 
patients at all grade levels experienced a similar educational burden. Also of note, larger 
households and single parents did not experience greater cost burdens, either financial or 
in terms of missed days of work. Future adjusted analyses will explore time-varying 
patient and family characteristics as potential predictors of greater financial toxicity. This 
is an important group to identify, as it may be associated with poorer outcomes and lower 
quality of life, and is potentially amenable to intervention. 
 
Our findings were comparable to previous studies in the U.S., Australia, and India 
showing a large proportion of parents experiencing work disruptions or employment 
changes during a child’s cancer therapy [46,52,53,63]. However, we did not find 
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significant differences in cost burden based on annual household income, or differences 
in days of school missed by age at diagnosis, which have been demonstrated in prior 
studies [52,59]. It is important to note that the variation in costs among families in our 
cohort was substantial, particularly in terms of out-of-pocket financial burden, as 
indicated by the large standard deviation values.  
 
To our knowledge, this is the largest study to date providing prospective data on many 
aspects of longitudinal costs to families during pediatric ALL therapy. This analysis 
benefits from frequent survey points to assess cost burden across therapy, in a cohort with 
the same diagnosis and comparable treatment protocols removing variability that is 
present in mixed-diagnosis cohorts. Our data also provides a comprehensive view of cost 
burden, with information on educational, occupational, and financial costs across therapy.  
 
These results should be interpreted in the context of certain limitations. Cost burden was 
based on parent-report for a prior 4 week time period, which may be affected by recall 
bias. However, the prospective study design attempts to decrease recall bias as much as 
possible. One previous study utilized a weekly cost diary method [64], but only obtained 
costs for 3 months of therapy in mixed pediatric cancers. Cost of living was not factored 
into current analyses, which may affect the association between household income and 
cost burden. Participation rates were 82% at timepoint 1, but decreased over therapy to 
60% at timepoint 5, which may introduce some selection bias. To date, the therapeutic 
study treatment arms are unblinded, so we were unable to compare financial toxicity in 
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patients with higher doses of methotrexate or more frequent chemotherapy pulses during 
maintenance therapy.  
 
In conclusion, the financial toxicity to families during treatment of average-risk ALL is 
substantial and persistent over the long duration of therapy. Annual household income 
and other patient characteristics may not be effective in identifying families at greatest 
risk for financial toxicity secondary to pediatric ALL therapy. Opportunity cost is an 
important consideration of overall cost burden, with a sizeable proportion of caregivers 
losing jobs and not taking employment opportunities during their child’s ALL treatment. 
Future analyses will work to further quantify this opportunity cost, and create models that 
adjust for patient factors and evaluate the association of events at one time point with 
future timepoints. We also plan to examine the association between family functioning 
and financial toxicity, and the relationship between financial toxicity and patient quality 
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Chapter 4: Conclusion  
 
Pediatric cancer treatments have made incredible advances in recent years, and the idea 
of “cure” has evolved from a hopeful concept to a reality for more than 80% of children 
and families facing a childhood cancer diagnosis. However, cure does not come without a 
cost. Previously, survival and relapse rate were the major focus of treatment protocols. As 
the field of pediatric oncology has progressed, we have come to appreciate the patient 
experience as an important metric.  
 
This thesis strove to demonstrate the financial toxicity families can experience during a 
child’s cancer treatment, as a means of quantifying one aspect of the extensive burden 
faced by these families. Measuring the impact of months of toxic therapies, frequent 
hospitalizations, and stress on children and families is difficult and complex. We used a 
comprehensive approach to calculate burden in these families, both in terms of areas of 
cost evaluated and frequency of burden assessment during therapy. Understanding the 
financial burden to pediatric cancer patients is essential, not only to work to lessen the 
impact of treatment on a family, but also to improve outcomes. Socioeconomic status has 
been shown in several studies to be associated with poorer outcomes in pediatric cancer, 
particularly in terms of survival [65-67]. In adults, a validated measure of financial 
toxicity has been developed (COmprehensive Score for financial Toxcitity, or COST) 
[68], and is associated with patient quality of life. A similar measure in pediatric patients 
would be beneficial to identify families with the greatest financial toxicity, and ideally to 
improve outcomes and quality of life. 
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This thesis also aimed to describe one of the late complications of treatment survivors 
may endure after therapy ends, bone health decrements and the risk of fracture. Survivors 
face a lifetime of health complications related to the physical and emotional effects of 
cancer treatment, and this burden may be immense. Surveillance for early identification 
of late complications of treatment is critical for timely intervention. However, detecting a 
late complication of treatment that has minimal impact on morbidity to a patient may 
pose an undue burden on a survivor. In our study, while decreased BMD was detected in 
a substantial proportion of survivors, the short- and long-term morbidity of this finding in 
terms of fracture outcomes requires further investigation to understand if this surveillance 
provides utility in reducing morbidity. 
 
A recent study from the Childhood Cancer Survivor Study examined financial burden in 
survivors of childhood cancer, linking the two concepts examined in this thesis. A key 
finding was that survivors spend a larger proportion of their income on out-of-pocket 
medical costs (>10%), an average of 30 years after treatment ended [69]. Childhood 
cancer survivors were also found to experience significantly greater opportunity costs as 
adults, estimated at $8,169 per survivor per year [70]. This further emphasizes the 
concept that childhood cancer patients and survivors face a burden that is greater than 
their peers, and that persists for many years after treatment ends.  
 
While many families described the overwhelming stress and unexpected costs they 
experienced during their child’s ALL therapy, many also reported that it brought their 
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family closer together. The quote below is one example of a family’s reflection on how 
life changed since their child’s cancer diagnosis.  
 
“Since learning of [child’s] leukemia we live life to the fullest and try to 
experience as much as possible. It has been a blessing in disguise in that it 
has taught us to appreciate life and not take anything for granted.” 
 
- Parent of a child finishing ALL treatment 
 
It is my hope that this work can add to the pediatric oncology field’s understanding of the 
burden that patients and their families may face both during and years after childhood 
cancer treatment, in order to work towards reducing this burden. Figure 1 displays a 
conceptual framework for the cost of pediatric cancer therapy. Using a holistic approach 
to evaluate a child’s cancer experience in the context of their family situation, long after 
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